

July 21, 2017

The Manager- Listing
BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing
National Stock Exchange of India Limited
Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Subject: Launch of Osimertinib Tablet 40 mg and 80 mg (Tagrisso™) in India

We refer to our communication dated May 29, 2017 with regard to the receipt of import and market permission in Form 45 (Marketing Authorization) from Drug Controller General of India for Osimertinib Tablets 40 mg and 80 mg (Tagrisso™).

With regard to the same, we now wish to update that AstraZeneca Pharma India Limited will launch Osimertinib 40 mg and 80 mg (Tagrisso™) in India on July 27, 2017.

Osimertinib 40 mg and 80 mg (Tagrisso™) is an oral anti-cancer drug for management of lung cancer. It is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an appropriate test, whose disease has progressed on or after EGFR TKI therapy.

Osimertinib (Tagrisso™) is the product of AstraZeneca group and has been approved in over 45 countries, including US, EU, Japan, China and other Asian countries.

Kindly take the same on record.

For AstraZeneca Pharma India Limited



Pratap Rudra
Company Secretary & Legal Counsel